Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Lilly eyes more cancer deals, but wary of CAR-T, gene therapy

Eli Lilly and Co. remains in the hunt for cancer drugs even after announcing an $8 billion purchase of Loxo Oncology, but the company plans to remain on the sidelines when it comes to two of the hottest areas of drug development.

Read More »

Healthcare deals raise pulse of U.S. lending in 2019

Bankers are diagnosing another robust year for U.S. healthcare lending as the first two big loans of 2019 include the largest-ever tie-up in the pharmaceutical sector, and more are expected.

Read More »

GlaxoSmithKline to look for early-stage assets: CEO

GlaxoSmithKline Plc will actively look to buy early-stage assets and partner with companies, the drugmaker’s chief executive officer said.

Read More »

Sanofi to pay Regeneron $462 million in revised immuno-oncology deal

Sanofi will pay Regeneron about $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body’s own immune system fight cancer.

Read More »

Selecta Biosciences Restructures, Cuts 36% of Staff

Selecta Biosciences announced restructuring efforts that include reducing the Watertown, Mass.-based company’s workforce by 36 percent.

Read More »

BioNTech teams up with Sanofi to target solid tumors

Germany-based BioNTech extended a three-year-old collaboration with Sanofi as the companies look to co-develop the first cancer immunotherapy candidate for solid tumors.

Read More »

Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal

Celgene Corp. and Bristol-Myers Squibb Co. will have to pay $2.2 billion if either of the drugmakers walks away from their $74 billion merger, according to a regulatory filing.

Read More »

Locus and Janssen Ink Potential $818 Million Deal

Locus Biosciences inked a collaboration and license deal with J&J’s Janssen Pharmaceutical to develop precision antibacterial therapies based on CRISPR-Cas3-enhanced bacteriophage.

Read More »

Bristol-Myers to buy Celgene for $74 billion

Bristol-Myers Squibb Co. will buy Celgene Corp. for about $74 billion, creating one of the largest pharmaceutical companies and combining two significant cancer medicine businesses.

Read More »

Boston Scientific Exercises Option to Buy Millipede

Boston Scientific exercised the company’s option to buy the remaining shares of Santa Rosa, Calif.-based Millipede for $325 million.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom